Medtech earnings were strong to kick off 2024, yet valuations pulled back in Q2. Even still, analysts maintain optimism for 2025, estimating double-digit growth for earnings per share across the sector. The tepid medtech M&A market is seeing rumblings of potential trends: Large strategics acquiring smaller public companies could encourage more of the same. This has not been mirrored in acquisitions of late-stage medtech startups, but that could change if IPOs remain sparse. PitchBook’s Q2 2024 Medtech Public Comp Sheet and Valuation Guide tracks stock performance, valuations, and market caps for key publicly traded companies.
Read the full article: PitchBook: Q2 2024 Medtech Public Comp Sheet and Valuation Guide //
Source: https://pitchbook.com/news/reports/q2-2024-medtech-public-comp-sheet-and-valuation-guide